彭布罗利珠单抗
肿瘤科
三阴性乳腺癌
医学
乳腺癌
内科学
阶段(地层学)
癌症
生物
免疫疗法
古生物学
作者
Peter Schmid,Javier Cortes,Rebecca Dent,Heather L. McArthur,Lajos Pusztai,Sherko Kümmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Seock‐Ah Im,Michael Untch,Peter A. Fasching,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fátima Cardoso,Xuan Zhou,Vassiliki Karantza,Konstantinos Tryfonidis,Gursel Aktan,Joyce O’Shaughnessy
标识
DOI:10.1056/nejmoa2409932
摘要
In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the addition of pembrolizumab to platinum-containing chemotherapy. Here we report the final results for overall survival.
科研通智能强力驱动
Strongly Powered by AbleSci AI